Functional MRI of Basal Ganglia Responsiveness to Levodopa in Parkinsonian Rhesus Monkeys

Functional MRI (fMRI) was used to study striatal sensitivity to levodopa in hemiparkinsonian rhesus monkeys. Responses consistent with increased neuronal activity were seen in areas whose normal dopaminergic input from the substantia nigra pars compacta had been ablated by MPTP. Sites of increased activity following levodopa included the lateral putamen, the ventral region of the caudate head, septal areas, and midlateral amygdala in the MPTP-lesioned hemisphere. Increased activity was also observed in the same areas in the nonlesioned hemisphere, but was less pronounced in spatial extent and magnitude, suggesting either subclinical contralateral damage and/or functional adaptations in the contralateral dopamine systems. The increases in neuronal activity following levodopa treatment were temporally correlated with increases in striatal dopamine levels. Chronic levodopa treatment reduced behavioral responsiveness to levodopa and abolished the fMRI response. These results suggest that fMRI can detect changes in dopamine receptor-mediated neuronal sensitivity to dopaminergic agents.

[1]  M. Muenter,et al.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. , 1971, Mayo Clinic proceedings.

[2]  B. Siesjö,et al.  Excessive increase in oxygen uptake and blood flow in the brain during amphetamine intoxication. , 1976, Acta Physiologica Scandinavica.

[3]  J. Mcculloch,et al.  Cerebral circulation: effect of stimulation and blockade of dopamine receptors. , 1977, The American journal of physiology.

[4]  R. Young,et al.  Different behavioral responses tol-DOPA after anterolateral or posterolateral hypothalamic injections of 6-hydroxydopamine , 1977, Brain Research.

[5]  B. Siesjö,et al.  Circulatory and metabolic effects in the brain induced by amphetamine sulphate. , 1978, Acta physiologica Scandinavica.

[6]  W J Schwartz,et al.  Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. , 1979, Science.

[7]  J. Korf,et al.  The Neurobiology of dopamine , 1979 .

[8]  G. Breese,et al.  Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. , 1979, The Journal of pharmacology and experimental therapeutics.

[9]  B. Sahakian,et al.  Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA , 1980, Pharmacology Biochemistry and Behavior.

[10]  Louis Sokoloff,et al.  Activity‐dependent Energy Metabolism in Rat Posterior Pituitary Primarily Reflects Sodium Pump Activity , 1980, Journal of neurochemistry.

[11]  J. Mcculloch,et al.  Cerebral circulatory and metabolic effects of piribedil. , 1980, European journal of pharmacology.

[12]  L. Sokoloff,et al.  Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. , 1981, Federation proceedings.

[13]  J. Mcculloch,et al.  Effect of Apomorphine on the Relationship between Local Cerebral Glucose Utilization and Local Cerebral Blood Flow (with an Appendix on its Statistical Analysis) , 1982, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  R. C. Collins,et al.  Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesions , 1983, Brain Research.

[15]  Martin Ingvar,et al.  Apomorphine-induced changes in local cerebral blood flow in normal rats and after lesions of the dopaminergic nigrostriatal bundle , 1983, Brain Research.

[16]  D Comar,et al.  Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[17]  Marcus E. Raichle,et al.  Regional blood flow in herniparkinsonism , 1985, Neurology.

[18]  R J Wise,et al.  The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. , 1985, Brain : a journal of neurology.

[19]  P. Goldman-Rakic,et al.  Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  D. Jacobowitz,et al.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.

[21]  J. Mcculloch,et al.  Catecholamines and the relationship between cerebral blood flow and glucose use. , 1986, The American journal of physiology.

[22]  G. Wooten,et al.  The effects ofl-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra , 1986, Brain Research.

[23]  M. Raichle,et al.  Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Jacobowitz,et al.  Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density , 1986, Brain Research.

[25]  C. D. Stern,et al.  Handbook of Chemical Neuroanatomy Methods in Chemical Neuroanatomy. Edited by A. Bjorklund and T. Hokfelt. Elsevier, Amsterdam, 1983. Cloth bound, 548 pp. UK £140. (Volume 1 in the series). , 1986, Neurochemistry International.

[26]  G. Wooten,et al.  Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  A. Crane,et al.  Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate. , 1987, Life sciences.

[28]  K. Jellinger,et al.  Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.

[29]  A. Crane,et al.  Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Bédard,et al.  Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys , 1988, Neuroscience Letters.

[31]  T. Di Paolo,et al.  Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. , 1988, European journal of pharmacology.

[32]  Ian Q. Whishaw,et al.  Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats , 1988, Brain Research.

[33]  D. Tank,et al.  Brain magnetic resonance imaging with contrast dependent on blood oxygenation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Abercrombie,et al.  Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats , 1990, Brain Research.

[35]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[36]  S. Ogawa Brain magnetic resonance imaging with contrast-dependent oxygenation , 1990 .

[37]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[38]  S. Boyce,et al.  Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis) , 1990, Brain Research.

[39]  J. Hsiao,et al.  In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis , 1990, Experimental Neurology.

[40]  T. Di Paolo,et al.  Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. , 1990, European journal of pharmacology.

[41]  R. Schwartzman,et al.  Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates , 1991, Brain Research.

[42]  O. Rascol,et al.  Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms. , 1991, British journal of clinical pharmacology.

[43]  John Sharkey,et al.  Acute cocaine administation: effects on local cerebral blood flow and metabolic demand in the rat , 1991, Brain Research.

[44]  A. Graybiel,et al.  Corticostriatal transformations in the primate somatosensory system. Projections from physiologically mapped body-part representations. , 1991, Journal of neurophysiology.

[45]  O. Hornykiewicz,et al.  Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey , 1991, Neuroscience.

[46]  I. Mitchell,et al.  A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. , 1992, Brain : a journal of neurology.

[47]  K. Takahashi,et al.  Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy. Comparison with Parkinson's disease. , 1992, Archives of neurology.

[48]  Agid Yves Levodopa‐induced dyskinesia , 1992 .

[49]  Ravi S. Menon,et al.  Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Gerhardt,et al.  Clearance of Exogenous Dopamine in Rat Dorsal Striatum and Nucleus Accumbens: Role of Metabolism and Effects of Locally Applied Uptake Inhibitors , 1993, Journal of neurochemistry.

[51]  M. Sambrook,et al.  Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism , 1993, Brain Research.

[52]  O. Hornykiewicz,et al.  Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. , 1993, Advances in neurology.

[53]  Z. Zhang,et al.  Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.

[54]  R. Schwartzman,et al.  Changes in brain dopamine receptors in MPTP parkinsonian monkeys followingL-dopa treatment , 1993, Brain Research.

[55]  M. Filion,et al.  Pathophysiology of Levodopa-Induced Dyskinesia: Changing Concepts , 1994 .

[56]  F. Hyder,et al.  Dynamic Magnetic Resonance Imaging of the Rat Brain during Forepaw Stimulation , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[57]  T. Paolo Modulation of brain dopamine transmission by sex steroids. , 1994 .

[58]  F. Calon,et al.  Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex , 1995, Brain Research.

[59]  M. Piercey,et al.  Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[60]  P. Jenner,et al.  Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) , 1995, Movement disorders : official journal of the Movement Disorder Society.

[61]  L. Sokoloff,et al.  Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys. , 1995, Neuroreport.

[62]  Don M. Gash,et al.  Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys , 1995, Neurobiology of Aging.

[63]  A Villringer,et al.  Coupling of brain activity and cerebral blood flow: basis of functional neuroimaging. , 1995, Cerebrovascular and brain metabolism reviews.

[64]  G. Gerhardt,et al.  Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions , 1995, Neuroscience Letters.

[65]  T. Di Paolo,et al.  Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. , 1996, Molecular pharmacology.

[66]  A H Andersen,et al.  Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI. , 1996, Magnetic resonance imaging.

[67]  M Hoehn-Berlage,et al.  Variation of functional MRI signal in response to frequency of somatosensory stimulation in α‐chloralose anesthetized rats , 1996, Magnetic resonance in medicine.

[68]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[69]  R. Todd,et al.  Dynamic Changes in Striatal Dopamine D2 and D3 Receptor Protein and mRNA in Response to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Denervation in Baboons , 1996, The Journal of Neuroscience.

[70]  D. Hilt,et al.  Glial cell line–derived neurotrophic factor–levodopa interactions and reduction of side effects in parkinsonian monkeys , 1997, Annals of neurology.

[71]  B R Rosen,et al.  Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data , 1997, Magnetic resonance in medicine.

[72]  M. Gado,et al.  PET Measurement of Dopamine D2 Receptor-Mediated Changes in Striatopallidal Function , 1997, The Journal of Neuroscience.